Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (SMC2829)
13/05/2026
Indication
In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
Concentrate for solution for infusion and solution for injection